Richard I. Steinhart

Filings by Richard I. Steinhart span 3 companies, the busiest being BioXcel Therapeutics, Inc., Actinium Pharmaceuticals, Inc. and Atossa Therapeutics, Inc. The record holds 23 filings, for trades running from 14 March 2023 to 2 September 2026.

No open-market purchase appears, only 1 sale worth €6,388. Other entries cover 4 share grants and 18 option exercises. In 2026 alone, the filings show no purchases and 1 sale.

The newest entry dates from 4 September 2026: a share grant, in Actinium Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.